Mittwoch, 22. Februar 2017

  • Pressemitteilung BoxID 61474

Net profit increased by more than 50%

Strategic and operational key projects well on track

(lifePR) (Bern, ) Despite major challenges during the first half year the Galenica Group managed to present a very positive result: net sales climbed to CHF 1,338.7 million (+8.3%) leading to consolidated earnings before interest, taxes, depreciation and amortisation (EBITDA) of CHF 232.0 million(+139.4%). Consolidated earnings before interest and taxes (EBIT) soared by 57.7% to CHF 124.1 million. The integration of Aspreva Pharmaceuticals Corporation into the newly formed Vifor Pharma is on track. The launch of Ferinject® in Switzerland started with tremendous success. Galexis is just about to move into its new distribution centre in Niederbipp.GaleniCare's pharmacy network was expanded by another 27 locations. Galenica expects its consolidated earnings to grow by approximately 40% in full-year 2008.

Galenica Group: Challenges mastered, consolidated earnings for 2008 expected to grow by approximately 40%

During the first half year the Galenica Group continued to push its strategic and operative key projects consistently. All the projects are under way as planned but are also tying up a large amount of resources. Despite this fact, the Galenica Group was able to compile a very positive result. With net sales of CHF 1,338.7 million the Group managed to increase them by 8.3% compared to the same period of 2007. Earnings before interest, taxes, depreciation and amortisation (EBITDA) grew by 139.4% to CHF 232.0 million while earnings before interest and taxes (EBIT) rose by 57.7% to CHF 124.1 million. Finally, the group profit soared by 52.1% to CHF 105.1 million. In the first half-year 2008, the investments in tangible assets - such as the construction of the new distribution centre in Niederbipp and the expansion of production capacity in St. Gallen - and intangible assets summed up to CHF 30.9 million.(Reed more from the attached file)

Galenica AG

Galenica is a diversified group active throughout the healthcare market which, among other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. The Galenica Group enjoys a leading position in all its business sectors - Pharma, Logistics, HealthCare Information and Retail. A large part of the Group's income is generated by international operations.

Additional information on the Galenica Group can be found at

Diese Pressemitteilungen könnten Sie auch interessieren

Fondsgebundene Rentenversicherung überzeugte im Scoring

, Finanzen & Versicherungen, uniVersa Versicherungen

Die ascore Das Scoring GmbH aus Hamburg hat die Angebote an fondsgebundenen Rentenversicherungen am Markt untersucht. Bis zu 36 Kriterien aus...

Preiserhöhung fürs Konto nicht immer wirksam

, Finanzen & Versicherungen, ARAG SE

Erhöhen die Banken die Kontoführungsgebühre­n, müssen sie ihre Kunden schriftlich darüber informieren. Aber Achtung! Die ARAG Experten raten...

Erfolgreiches Geschäftsjahr 2016 für die Sparkasse Bremen

, Finanzen & Versicherungen, Die Sparkasse Bremen AG

. Gewinn stieg deutlich auf über 32 Millionen Euro Klarer Marktführer in Bremen bei Privat- und Firmenkunden Auszeichnung als einer der besten...